The new classification of lung adenocarcinomas according to the American Thoracic Society and the European Respiratory Society: New recommendations to improve management
##plugins.themes.academic_pro.article.main##
Abstract
Background: Lung cancer represents a major public health problem.It represents the first cause of mortality by cancer in Tunisia. Its incidence reaches 40% of lung cancers. Its clinical, radiologic and molecular aspects have been improved inducing the necessity of a new classification which will consider the necessity of a multidisciplinary management.
aim: To highlight the new classification of lung adenocarcinomas and to present the major recommendations.
methods: We tried to present the main recommendations of the American Thoracic Society and the European Respiratory Society of lung adenocarcinoma.
results: This new classification identifies pre-invasive lesions represented by in-situ adenocarcinoma (the ancient bronchioloalveolar), the micro-invasive adenocarcinoma and invasive adenocarcinoma. The latter have been divided in sub-types according to the predominant architectural features. Thus, three groups of invasive adenocarcinoma with presumed different prognoses have been identified: the lepidic predominant adenocarcinoma which has a good prognosis, the micro-papillary and solid predominant adenocarcinomas which have a bad prognosis and the papillary and acinar adenocarcinomas which have an intermediate prognosis. All these entities have specific diagnostic features and criteria. These recommendations are available for biopsies and surgical resected specimen.
Conclusion: The new classification of lung adenocarcinoma puts emphasis on the necessity of a multi-disciplinary management of these tumors in order to improve their prognosis. It identifies new entities with different prognoses that could justify specific modalities of treatment and follow up.
aim: To highlight the new classification of lung adenocarcinomas and to present the major recommendations.
methods: We tried to present the main recommendations of the American Thoracic Society and the European Respiratory Society of lung adenocarcinoma.
results: This new classification identifies pre-invasive lesions represented by in-situ adenocarcinoma (the ancient bronchioloalveolar), the micro-invasive adenocarcinoma and invasive adenocarcinoma. The latter have been divided in sub-types according to the predominant architectural features. Thus, three groups of invasive adenocarcinoma with presumed different prognoses have been identified: the lepidic predominant adenocarcinoma which has a good prognosis, the micro-papillary and solid predominant adenocarcinomas which have a bad prognosis and the papillary and acinar adenocarcinomas which have an intermediate prognosis. All these entities have specific diagnostic features and criteria. These recommendations are available for biopsies and surgical resected specimen.
Conclusion: The new classification of lung adenocarcinoma puts emphasis on the necessity of a multi-disciplinary management of these tumors in order to improve their prognosis. It identifies new entities with different prognoses that could justify specific modalities of treatment and follow up.
Keywords:
Lung adenocarcinoma, classification, in situ adenocarcinoma##plugins.themes.academic_pro.article.details##
References
- Travis WD, Brambilla E, Noguchi M, et al. International Association for the study of Lung Cancer/American Thoracic Society/ European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011;6:244-85.
- World Health Organization. Histological typing of Lung Tumours, 1st ed. Geneva: World Health Organization, 1967.
- World Health Organization. Histological Typing of Lung Tumours, 2ed. Geneva: World Health Organization, 1981.
- Travis WD, Colby TV, Corrin B, et al. Histological Typing of Lung and Pleural tumors. In collaboration with LH Sobin and Pathologists from 14 countries. World health Organization. International Histological Classification of Tumors. Third Edition. Berlin, Heidelberg, New York: Springer; 1999.
- Travis W, Brambilla E, Muller-Hermelink HK, et al. World Health organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and heart. Lyon:IARC Press;2004.
- Travis WD, Brambilla E, Van Schil P, et al. Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification. Eur Respir J 2011;38:239-43.
- Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-pachtaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-57.
- Yu J, Kane S, Wu J, et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res. 2009;15:3023-28
- Kawahara A, Yamamoto C, Nakashima K, et al. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutationspecific antibodies for immunohistochemical analysis. Clin Cancer Res. 2010;16:3163-70
- Shaw AT, Yeap BY, Mino-Kenudson M, et al. Molecular diagnosis of activating EGFR mutations in non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27:4247-53.
- Kwak EL, Camidge DR, Clark J, et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor. J Clin Oncol. 2009;27:15s.